What is CorMedix's melinta portfolio — total revenue?

CorMedix (CRMD) reported melinta portfolio — total revenue of $24.41M in Q1 2026.

What does melinta portfolio — total revenue mean?

This metric represents the total gross revenue generated by the specific product portfolio or business segment identified as Melinta. It reflects the aggregate sales performance and market adoption of these therapeutic assets within the company's broader commercial operations. Monitoring this figure helps investors assess the revenue contribution and growth trajectory of this specific business unit.

CorMedix (CRMD) Melinta Portfolio — Total Revenue

Screener

Other product segments

DefenCath

$97.51M+150%

Contract revenue

$5.51M—

Similar metrics at other companies

RITMInvestment Portfolio — Total Revenue

$136.12M+29.5%

IBRXOther revenues — Total Revenue

$39K+388%

MARNet fee revenues — Total Revenue

$1.4B+12.1%

BIIBMS Product Revenues — Total Revenue

$963.3M-13.0%

PTH

PTHSNet product revenues — Total Revenue

$10.67M—

LTHTotal center revenue — Total Revenue

$837.4M+13.8%

Other financials

Income statement

See full

Revenue$127.4M+226%

Gross profit$115.4M+207%

Operating income$63.7M+216%

Net income$38.6M+87.0%

EPS (diluted)$0.43+43.3%

Balance sheet

See full

Cash & equivalents$179.1M+170%

Total debt$4.3M+729%

Total equity$437.0M+280%

Total assets$815.6M+445%

Cash flow

See full

Operating cash flow$42.4M+115%

CapEx$729.0K+7,190%

Free cash flow$41.7M+111%

Valuation

See full

Market cap$583.68M-22.4%

P/E3.2×—

P/S1.5×-4.7×

Profitability

See full

Gross margin91.9%-3.5pp

Operating margin48.4%—

Net margin45.2%—

FCF margin48.7%+38.8pp

Returns & leverage

See full

Return on equity65.6%—

Debt / equity0×0.0×

Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: CorMedix’s 10-Q, filed May 14, 2026.

Filed: May 14, 2026, 8:00 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001410098-26-000021

Line item	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Product Sales:
DefenCath	$97,511	$39,082
Melinta Portfolio	24,405	-
Total product sales	121,916	39,082
Contract Revenue	5,511	-
Total Revenues	$127,427	$39,082

Item 1. Unaudited Condensed Consolidated Financial Statements.

FAQ

What is CorMedix's melinta portfolio — total revenue?: CorMedix (CRMD) reported melinta portfolio — total revenue of $24.41M in Q1 2026.
What does melinta portfolio — total revenue mean?: This metric represents the total gross revenue generated by the specific product portfolio or business segment identified as Melinta. It reflects the aggregate sales performance and market adoption of these therapeutic assets within the company's broader commercial operations. Monitoring this figure helps investors assess the revenue contribution and growth trajectory of this specific business unit.